| 乳腺癌分子分型在新辅助化疗疗效和预后中的预测作用 |
| |
| 引用本文： | 吴建南,李顺荣,顾然,萧俏珍,苏逢锡.乳腺癌分子分型在新辅助化疗疗效和预后中的预测作用[J].中山大学学报(医学科学版),2011,32(3):383. |
| |
| 作者姓名： | 吴建南 李顺荣 顾然 萧俏珍 苏逢锡 |
| |
| 作者单位： | 中山大学孙逸仙纪念医院乳腺肿瘤医学部,广东 广州 510120 |
| |
| 摘 要： | 【目的】 探讨乳腺癌分子分型在表阿霉素联合多西紫杉醇方案(ET方案)化疗敏感性及预后方面的预测作用。【方法】 对接受ET新辅助化疗方案治疗的244例乳腺癌患者进行回顾性分析。依据免疫组化雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)表达水平将乳腺癌分为Luminal、HER-2+和Basal-like 3个分子亚型,分析3个分子亚型患者的病理疗效及远期生存的差别。【结果】 244例患者中,167(68.4%)例为Luminal亚型,43(17.6%)例为HER2+亚型,34(13.9%)例为Basal-like亚型｡Basal-like亚型与HER2+亚型的病理完全缓解率(pCR)分别为29.4%、25.6%,明显高于Luminal亚型的12.0% (P = 0.011)。Basal-like亚型与HER2+亚型患者,特别是新辅助化疗后仍有癌残留的患者,其5年无病生存率(DFS)明显低于Luminal亚型(P < 0.05)。Basal-like亚型与HER2+亚型患者,特别是新辅助化疗后仍有癌残留的患者,其5年总生存率(OS)亦明显低于Luminal亚型(P<0.05)。获得pCR的乳腺癌患者5年的DFS和OS均明显高于化疗后仍有癌残留的患者(P值分别为P < 0.001,P=0.003)。【结论】乳腺癌分子分型能作为乳腺癌的病理完全缓解独立预测因子。相比于Luminal亚型,Basal-like亚型和HER2+亚型的pCR率更高,但远期生存率却较差。
|
| 关 键 词： | 乳腺癌 分子分型 新辅助化疗 预后 |
| 收稿时间： | 2010-11-25; |
Predictive Role of Breast Cancer Molecular Subtype in Response and Outcome of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy |
| |
| WU Jian-nan,LI Shun-rong,GU Ran,XIAO Qiao-zhen,SU Feng-xi.Predictive Role of Breast Cancer Molecular Subtype in Response and Outcome of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy[J].Journal of Sun Yatsen University(Medical Sciences),2011,32(3):383. |
| |
| Authors: | WU Jian-nan LI Shun-rong GU Ran XIAO Qiao-zhen SU Feng-xi |
| |
| Affiliation: | Department of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China |
| |
| Abstract: | Objective] To investigate the predictive role of breast cancer molecular subtype in the response and outcome of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin chemotherapy.Methods]Two hundred and forty-four patients treated with neoadjuvant chemotherapy were included in this retrospective study.Molecular subtypes were constructed from immunohistochemical results of estrogen receptor(ER),progesterone receptor(PR) and HER2 status,which were classified as Luminal,HER2 positive and ... |
| |
| Keywords: | breast cancer molecular subtype neoadjuvant chemotherapy prognosis |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《中山大学学报(医学科学版)》浏览原始摘要信息 |
|
点击此处可从《中山大学学报(医学科学版)》下载全文 |
|
